Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
500 participants
OBSERVATIONAL
2015-01-31
2023-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Assessment of ProEnkephalin to Detect Acute Kidney Injury (AKI)
NCT04019314
NGAL and Renal Resistive Index in the Diagnosis and Prognosis of Sepsis-associated AKI
NCT05374759
Inflammatory Mediators of Acute Kidney Injury in Intensive Care
NCT03720860
Investigating Different Anticoagulants for Renal Replacement Therapy
NCT02669589
Assessment of Kidney Function and Osteomuscular Status After Critical Care
NCT04980092
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AKI
Patients developing AKI during the ICU stay
Blood draw for measurement of MIF
Observational study, no intervention
No AKI
Matched controls not developing AKI during the ICU stay
Blood draw for measurement of MIF
Observational study, no intervention
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Blood draw for measurement of MIF
Observational study, no intervention
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Exclusion Criteria
* Patients with chronic dialysis
* Patients with continuous hemodialysis, hemofiltration or hemodiafiltration within 4 weeks prior to the study
* Patients with an expected length of ICU stay shorter than 3 days
* Patients with a low probability of surviving the first 2 days after ICU admission
* Pregnancy and nursing
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medical University of Vienna
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
David M Baron, MD, PhD
Univ.-Ass.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Medical University of Vienna
Vienna, , Austria
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1680/2014
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.